La chaîne d'options affiche les données clés des options sur actions de PyroGenesis à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour PyroGenesis..

PyroGenesis (OTC:PYRGF) Stock, Chaîne d'Options

PyroGenesis Inc formerly, PyroGenesis Canada Inc is engaged in the design, development, manufacture, and commercialization of advanced plasma processes and systems. It provides technical & manufacturing expertise, cutting-edge contract research, and turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil & gas, and environmental industries. Its Product categories include Aluminum & Zinc Dross Recovery, Plasma Atomized Metal Powders, Waste Management, Innovation/Custom Process Development, and Plasma Torches. Its geographical segments are Brazil, Canada, United States, Mexico, Israel, Saudi Arabia, India, Africa, England, Germany, Netherlands, Poland, Spain and Vietnam. The Majority of revenue is generated from Canada.

PyroGenesis Inc

Macquarie analyst Tao Qiu maintains Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) with a Outperform and maintains $8 price target.

News

Price Target

Analyst Ratings

Macquarie Maintains Outperform on Brookdale Senior Living, Maintains $8 Price Target

RBC Capital analyst Irene Nattel maintains Casey's General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) with a Sector Perform and raises the price target from $430 to $438.

CASY

RBC Capital Maintains Sector Perform on Casey's General Stores, Raises Price Target to $438

<a href="https://www.niaid.nih.gov/news-events/tecovirimat-safe-ineffective-treatment-clade-ii-mpox">https://www.niaid.nih.gov/news-events/tecovirimat-safe-ineffective-treatment-clade-ii-mpox</a>
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial sponsored by the National Institutes of Health (NIH). The&nbsp;<a href="https://www.niaid.nih.gov/news-events/nih-study-finds-tecovirimat-was-safe-did-not-improve-mpox-resolution-or-pain">trial enrollment was stopped in late 2024</a> when an interim analysis showed that tecovirimat monotherapy was ineffective in the study population. Detailed results were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

Biotech

General

SIGA

'Tecovirimat Is Safe But Ineffective As Treatment For Clade II Mpox' - NIH

RBC Capital analyst James McGarragle reiterates CAE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CAE#TSX">CAE</a>) with a Outperform and maintains C$43 price target.

Reiteration

TSX:CAE

RBC Capital Reiterates Outperform on CAE, Maintains C$43 Price Target

Macquarie analyst Paul Golding maintains Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) with a Neutral and lowers the price target from $195 to $185.

Macquarie Maintains Neutral on Vail Resorts, Lowers Price Target to $185

RBC Capital analyst James McGarragle reiterates CAE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAE#NYSE">CAE</a>) with a Outperform and maintains $43 price target.

RBC Capital Reiterates Outperform on CAE, Maintains $43 Price Target

Investors looking for a strategic way to engage with the market while managing risk now have a new option. Measured Risk Portfolios (MRP) has launched the MRP SynthEquity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNTH#NYSE">SNTH</a>), an <a href="https://www.benzinga.com/etfs">actively managed exchange-traded fund</a> designed for long-term capital appreciation. 
To enhance stability, the fund follows a quarterly laddered approach to its U.S. Treasury investments. The strategy primarily includes high-yielding Treasuries that mature around the 15th of March, June, September, and December, maintaining an overall portfolio duration of about six months.
Also: <a href="https://www.benzinga.com/25/03/44260566/tov-etfs-rapid-rise-100m-milestone-reached-in-under-two-weeks">TOV ETF&#8217;s Rapid Rise: $100 Million Milestone Reached In Under Two Weeks</a>
This strategic blend of options exposure and Treasuries is intended to provide a safeguard against downside risk, with an aim to cap potential losses at approximately 15% over any rolling one-year period.
The fund carries a net expense ratio of 95 basis points.
SNTH employs a two-pronged investment <a href="https://www.sec.gov/Archives/edgar/data/1722388/000183988225011390/snth-497k_022625.htm">strategy </a>to balance market participation with risk management.
The first component involves investing in options contracts on the S&amp;P 500 Index. By using standardized exchange-traded or FLEX options, the fund aims to generate returns through synthetic long exposure.
Complementing this options strategy, SNTH maintains a U.S. Treasury portfolio. This portfolio plays a dual role: mitigating risk and generating income.
For investors who are cautious about market uncertainties, SNTH offers a compelling solution. By staying engaged with the S&amp;P 500 while cushioning against volatility, the fund presents an attractive option for those seeking growth with risk mitigation.
Additionally, as an actively managed ETF, SNTH is positioned to respond to macroeconomic shifts more effectively than passive strategies. This dynamic management approach may provide an edge in navigating changing market conditions.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/travel/25/03/44263340/turbulence-ahead-3-etfs-hit-by-slump-in-travel-stocks">Turbulence Ahead: 3 ETFs Hit By Slump In Travel Stocks</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

Bitwise Funds Trust Bitwise Bitcoin Standard Corporations ETF

OWNB

SNTH

New ETF Balances S&P 500 Exposure With Treasury Stability To Limit Losses

Shares of Kohls Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) tanked in early trading on Wednesday, after the company <a href="https://www.benzinga.com/news/earnings/25/03/44246040/kohls-anticipates-sales-and-profit-dip-in-2025-slashes-dividend-by-75-stock-tanks">reported its fourth-quarter results</a>.
The company controlled its SG&amp;A expenses to report a "solid" earnings beat, despite a significant gross margin miss, according to Telsey Advisory Group.
The Kohls Thesis: Analyst <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5888c53977f9dd0001877a22/dana-telsey">Dana Telsey</a> maintained a Market Perform rating, while cutting the price target from $13 to $10.
The Kohls Thesis: Despite the earnings beat, the company announced its 2025 outlook significantly below "the market&#8217;s prior (already-modest) expectations," Telsey said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The CEO indicated strategic initiatives will be undertaken over the next few quarters and that the turnaround will take time to complete, as Kohls is "a long lead-time business," she added.
"New leadership will look to bring stabilization to the business following several years of volatile performance, but visibility to a timeline to a turnaround to better profitability is challenging in our view, particularly against an increasingly uncertain macro backdrop," the analyst wrote.
Even after improvements in the assortment, value proposition and customer experience, it will take time for Kohls to win back consumers, she further stated.
KSS Price Action: Shares of Kohls had declined by 7.38% to $8.48 at the time of publication on Wednesday.
Read More: <a href="https://www.benzinga.com/25/03/44262764/kohls-ceo-warns-of-pretty-challenging-environment-for-consumers-expects-value-seeking-to-grow-over-next-3-months">Kohl&#8217;s CEO Warns Of &#8216;Pretty Challenging&#8217; Environment For Consumers</a>
Photo: Shutterstock

Earnings

Trading Ideas

Kohls Smashes Q4 Earnings Expectations, Analyst Cuts Forecast On Disappointing Guidance, Turnaround Underway

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.exein.io%2F&amp;esheet=54223118&amp;newsitemid=20250312141274&amp;lan=en-US&amp;anchor=Exein&amp;index=1&amp;md5=a1c89cdc80227e006c960c1855a08751">Exein</a>, the embedded IoT cybersecurity company, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.supermicro.com%2Fen%2F&amp;esheet=54223118&amp;newsitemid=20250312141274&amp;lan=en-US&amp;anchor=Supermicro&amp;index=2&amp;md5=9be9ce40c66f46a336f24b25e6a1e40b">Supermicro</a>, a global leader in application-optimized total IT solutions, have announced a partnership to redefine embedded security. Exein and Supermicro's collaboration will see Exein's cutting-edge embedded security solutions integrated into Supermicro's industry-leading hardware, ensuring unprecedented protection for enterprises worldwide.
Together, Exein and Supermicro are raising the bar for cybersecurity in edge computing, IoT, and critical infrastructure—securing the future, one device at a time. With Exein's AI-driven security built directly into Supermicro's hardware, businesses can now deploy infrastructure with zero-trust security from the ground up—ensuring resilience against evolving cyber threats.

SMCI

Exein Partners With Supermicro To Redefine The Future Of Embedded Security; Collaboration Will See Exein's Embedded Security Solutions Integrated Into Supermicro's Hardware, Ensuring Unprecedented Protection For Enterprises Worldwide

Macquarie analyst Aaron Lee maintains PLAYSTUDIOS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYPS#NASDAQ">MYPS</a>) with a Neutral and lowers the price target from $2 to $1.5.

MYPS

Macquarie Maintains Neutral on PLAYSTUDIOS, Lowers Price Target to $1.5

<ul>
<li>New landmark peer-reviewed paper published in Science, "Beyond-Classical Computation in Quantum Simulation," unequivocally validates D-Wave's achievement of the world's first and only demonstration of quantum computational supremacy on a useful, real-world problem</li>
<li>Research shows D-Wave annealing quantum computer performs magnetic materials simulation in minutes that would take nearly one million years and more than the world's annual electricity consumption to solve using a classical supercomputer built with GPU clusters</li>
<li>D-Wave Advantage2 annealing quantum computer prototype used in supremacy achievement, a testament to the system's remarkable performance capabilities</li>
</ul>
D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) ("D-Wave" or the "Company"), a leader in quantum computing systems, software, and services and the world's first commercial supplier of quantum computers, today announced a scientific breakthrough <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.science.org%2Fdoi%2F10.1126%2Fscience.ado6285&amp;esheet=54222980&amp;newsitemid=20250312803163&amp;lan=en-US&amp;anchor=published+in+the+esteemed+journal+Science&amp;index=1&amp;md5=c0a0f788cd8e5c69f24fc73b23d9514e">published in the esteemed journal Science</a>, confirming that its annealing quantum computer outperformed one of the world's most powerful classical supercomputers in solving complex magnetic materials simulation problems with relevance to materials discovery. The new landmark peer-reviewed paper, "Beyond-Classical Computation in Quantum Simulation," validates this achievement as the world's first and only demonstration of quantum computational supremacy on a useful problem.

QBTS

D-Wave Quantum Announces A Scientific Breakthrough Published In The Esteemed Journal Science, Confirming That Its Annealing Quantum Computer Outperformed One Of The World's Most Powerful Classical Supercomputers In Solving Complex Magnetic Materials Simulation Problems With Relevance To Materials Discovery

<ul>
<li>Results from the phase IIb study, EMBRACE, demonstrate that N6LS, a bNAb administered every four months, effectively maintained undetectable viral load when combined with cabotegravir long-acting (CAB LA)</li>
<li>Results add to the growing body of evidence that N6LS is a potent antiviral that can function as a component of a complete antiretroviral regimen</li>
<li>EMBRACE study to continue investigating a combination of N6LS dosed at six months with CAB LA</li>
</ul>
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company's EMBRACE phase IIb study.1 The study found that N6LS (VH3810109 or VH109), given every four months in combination with monthly cabotegravir long-acting (CAB LA), successfully kept viral levels suppressed in adults living with HIV who were already stable on treatment. It was also well tolerated by participants.
These results were presented today at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, U.S.

ViiV Healthcare Announces Findings From The Company's EMBRACE Phase IIb Study; N6LS Maintains Viral Suppression In Long-acting Treatment Of HIV

High-rolling investors have positioned themselves bearish on Talen Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLN#NASDAQ">TLN</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in TLN often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 10 options trades for Talen Energy. This is not a typical pattern.
The sentiment among these major traders is split, with 40% bullish and 50% bearish. Among all the options we identified, there was one put, amounting to $60,518, and 9 calls, totaling $1,050,311.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $165.0 to $210.0 for Talen Energy over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Talen Energy's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Talen Energy's substantial trades, within a strike price spectrum from $165.0 to $210.0 over the preceding 30 days.
<h3>Talen Energy Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741793561_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$22.0</td>
<td>$21.6</td>
<td>$22.0</td>
<td>$170.00</td>
<td>$220.0K</td>
<td align="right">561</td>
<td align="right">101</td>
</tr>
<tr>
<td>TLN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$23.5</td>
<td>$23.0</td>
<td>$23.5</td>
<td>$170.00</td>
<td>$204.4K</td>
<td align="right">561</td>
<td align="right">188</td>
</tr>
<tr>
<td>TLN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$15.4</td>
<td>$14.3</td>
<td>$15.4</td>
<td>$185.00</td>
<td>$154.0K</td>
<td align="right">151</td>
<td align="right">0</td>
</tr>
<tr>
<td>TLN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$23.5</td>
<td>$23.0</td>
<td>$23.0</td>
<td>$170.00</td>
<td>$128.8K</td>
<td align="right">561</td>
<td align="right">244</td>
</tr>
<tr>
<td>TLN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$23.5</td>
<td>$22.1</td>
<td>$23.0</td>
<td>$170.00</td>
<td>$101.2K</td>
<td align="right">561</td>
<td align="right">288</td>
</tr>
</tbody>
</table>

<h3>About Talen Energy</h3>
Talen Energy Corp is an independent power producer and energy infrastructure company. The company owns and operates approximately 10.7 gigawatts of power infrastructure in the United States. The group produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, including PJM and WECC, with its generation fleet located in the Mid-Atlantic and Montana.
In light of the recent options history for Talen Energy, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Talen Energy</h3>
<ul>
<li>Currently trading with a volume of 1,234,914, the TLN's price is up by 8.5%, now at $191.56. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 153 days.</li>
</ul>
<h3>Professional Analyst Ratings for Talen Energy</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $262.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley downgraded its action to Overweight with a price target of $243. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Talen Energy, maintaining a target price of $282. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Talen Energy options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

Market Whales and Their Recent Bets on TLN Options

Whales with a lot of money to spend have taken a noticeably bearish stance on Snowflake.
Looking at options history for Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 53% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $217,803 and 9, calls, for a total amount of $418,871.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $120.0 to $180.0 for Snowflake over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Snowflake's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Snowflake's significant trades, within a strike price range of $120.0 to $180.0, over the past month.
<h3>Snowflake 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741793556_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$7.3</td>
<td>$7.1</td>
<td>$7.3</td>
<td>$170.00</td>
<td>$104.3K</td>
<td>1.2K</td>
<td align="right">145</td>
</tr>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$37.75</td>
<td>$32.75</td>
<td>$34.73</td>
<td>$160.00</td>
<td>$86.8K</td>
<td>26</td>
<td align="right">25</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$42.65</td>
<td>$41.65</td>
<td>$41.65</td>
<td>$120.00</td>
<td>$83.3K</td>
<td>181</td>
<td align="right">20</td>
</tr>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/14/25</td>
<td>$4.0</td>
<td>$3.85</td>
<td>$4.0</td>
<td>$155.00</td>
<td>$58.8K</td>
<td>394</td>
<td align="right">188</td>
</tr>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$2.25</td>
<td>$2.2</td>
<td>$2.2</td>
<td>$150.00</td>
<td>$41.3K</td>
<td>1.2K</td>
<td align="right">115</td>
</tr>
</tbody>
</table>

<h3>About Snowflake</h3>
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that went public in 2020. To date, the company has over 3,000 customers, including nearly 30% of the Fortune 500. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to buy and ingest data, while its data solutions can be hosted on various public clouds.
Having examined the options trading patterns of Snowflake, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Snowflake's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,872,371, the price of SNOW is up by 1.56%, reaching $152.24.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 70 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Snowflake</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $216.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Wolfe Research upgrades its rating to Outperform with a revised price target of $235. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Snowflake with a target price of $190. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Snowflake, which currently sits at a price target of $215. 
&#x2A; An analyst from Cantor Fitzgerald has decided to maintain their Overweight rating on Snowflake, which currently sits at a price target of $228. 
&#x2A; An analyst from Loop Capital persists with their Buy rating on Snowflake, maintaining a target price of $215. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Snowflake, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

SNOW

Unpacking the Latest Options Trading Trends in Snowflake

RBC Capital analyst Shagun Singh downgrades Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) from Outperform to Sector Perform and lowers the price target from $11 to $5.5.

Downgrades

ZYXI

RBC Capital Downgrades Zynex to Sector Perform, Lowers Price Target to $5.5

Deep-pocketed investors have adopted a bearish approach towards Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in RCL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Royal Caribbean Gr. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 23% leaning bullish and 53% bearish. Among these notable options, 7 are puts, totaling $260,493, and 6 are calls, amounting to $422,608.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $180.0 to $230.0 for Royal Caribbean Gr over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Royal Caribbean Gr's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Royal Caribbean Gr's whale activity within a strike price range from $180.0 to $230.0 in the last 30 days. 
<h3>Royal Caribbean Gr Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741793550_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$14.05</td>
<td>$13.75</td>
<td>$13.75</td>
<td>$210.00</td>
<td>$214.5K</td>
<td align="right">55</td>
<td align="right">175</td>
</tr>
<tr>
<td>RCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$11.7</td>
<td>$11.25</td>
<td>$11.7</td>
<td>$180.00</td>
<td>$67.8K</td>
<td align="right">57</td>
<td align="right">64</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$14.0</td>
<td>$13.4</td>
<td>$13.75</td>
<td>$210.00</td>
<td>$60.5K</td>
<td align="right">55</td>
<td align="right">219</td>
</tr>
<tr>
<td>RCL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$41.3</td>
<td>$41.25</td>
<td>$41.25</td>
<td>$230.00</td>
<td>$57.7K</td>
<td align="right">36</td>
<td align="right">14</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$24.75</td>
<td>$24.5</td>
<td>$24.5</td>
<td>$220.00</td>
<td>$46.5K</td>
<td align="right">123</td>
<td align="right">26</td>
</tr>
</tbody>
</table>

<h3>About Royal Caribbean Gr</h3>
Royal Caribbean is the world's second-largest cruise company, operating 66 ships across five global and partner brands in the cruise vacation industry. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises. The selection of brands in the portfolio allows Royal to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in 2021 and plans to launch its new Celebrity River Cruise brand in 2027.
After a thorough review of the options trading surrounding Royal Caribbean Gr, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Royal Caribbean Gr's Current Market Status</h3>
<ul>
<li>With a trading volume of 933,382, the price of RCL is up by 0.46%, reaching $208.13.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 43 days from now.</li>
</ul>
<h3>What The Experts Say On Royal Caribbean Gr</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $272.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Susquehanna persists with their Positive rating on Royal Caribbean Gr, maintaining a target price of $295. 
&#x2A; Showing optimism, an analyst from Loop Capital upgrades its rating to Buy with a revised price target of $250. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Royal Caribbean Gr, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Smart Money Is Betting Big In RCL Options

The stock of The Goldman Sachs Group, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) is consolidating Wednesday. This follows a decline of more than 20% that began in the middle of February.
There is a chance of a reversal and a move higher. The stock is extremely oversold. This is why our team of technical analysts has made it our Stock of the Day.
Most of the time a stock stays within its typical or usual trading range. If traders are aggressive and push the price above the range, the stock is considered to be ‘overbought'. If it is below the range, then it is considered to be ‘oversold'.
This is important.
Many trading strategies are based on the concept of reversion to the mean. If a stock is overbought, traders will enter the market as sellers because they will be anticipating a move lower. If the stock is oversold, they will anticipate a move higher and enter the market as buyers.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/03/44269301/trumps-25-tariffs-on-steel-and-aluminum-imports-take-effect-eu-retaliates-us-steel-nucor-century-aluminum-and-other-domestic-stocks-cheer">Trump&#8217;s 25% Tariffs On Steel And Aluminum Imports Take Effect, EU Retaliates: US Steel, Nucor, Century Aluminum And Other Domestic Stocks Cheer</a>
There are many ways to determine if a stock is overbought or oversold. One of the most common is the Relative Strength Index (RSI). This is on the bottom part of the chart.
If the blue line crosses below the horizontal red line, it indicates oversold conditions. As you can see, this is the case now. This could draw in buyers who may end up pushing the price higher.
Some traders don't try to catch the exact top or exact bottom. They wait for a trend to develop and then jump in.
For Goldman, there is a good chance there will be resistance around the $558.00 level. If so, it could put a top on it. This means some will wait to see if this resistance breaks before they buy.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="565" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12112434/1-3-1024x565.png" alt="" class="wp-image-821208" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12112434/1-3-1024x565.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12112434/1-3-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12112434/1-3-768x424.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12112434/1-3.png 1485w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
As you can see on the chart, this level had been support. Now that the price is lower, some who purchased shares at the support regret doing so. Many decide to eventually get out at breakeven if they can. So, if the stock rallies back to $558.00, they will place sell orders.
If there is a large amount of these sell orders, it could create resistance. But if this resistance breaks, there is a good chance Goldman will keep moving higher.
Read Next: <a href="https://www.benzinga.com/news/25/03/44278060/trump-to-nominate-feds-michelle-bowman-as-top-banking-regulator-report">Trump To Nominate Fed&#8217;s Michelle Bowman As Top Banking Regulator: Report</a>
Photo: Shutterstock

Technicals

Stock Of The Day – Is The Goldman Sachs Selloff Finally Over?

Morningstar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NASDAQ">MORN</a>) has outperformed the market over the past 15 years by 26.44% on an annualized basis producing an average annual return of 37.38%. Currently, Morningstar has a market capitalization of $12.20 billion. 
Buying $100 In MORN: If an investor had bought $100 of MORN stock 15 years ago, it would be worth $11,694.77 today based on a price of $284.43 for MORN at the time of writing.
<h3>Morningstar's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741793411_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MORN

Here's How Much $100 Invested In Morningstar 15 Years Ago Would Be Worth Today

DOR/ISL demonstrated non-inferiority and a similar safety profile to comparator antiretroviral therapies in adults with virologically suppressed HIV-1
Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, today announced the presentation of positive results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100mg/0.25mg)] in adults with HIV-1 infection that is virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamidei [BIC/FTC/TAF (50mg/200mg/25mg)] in trial <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05630755&amp;esheet=54223136&amp;newsitemid=20250312706063&amp;lan=en-US&amp;anchor=MK-8591A-052&amp;index=1&amp;md5=d962319798a591d93c498e4e23a89f2f">MK-8591A-052</a>) or antiretroviral therapy [baseline antiretroviral therapy (bART)] in trial <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05631093%3Fterm%3Dislatravir%26page%3D2%26rank%3D20&amp;esheet=54223136&amp;newsitemid=20250312706063&amp;lan=en-US&amp;anchor=MK-8591A-051&amp;index=2&amp;md5=9f12d7e4233e638166ba99975cc400aa">MK-8591A-051</a>. In both trials, DOR/ISL met the primary efficacy success criterion for non-inferiority to comparator antiretroviral therapies and primary safety objectives at Week 48. The findings will be shared in late-breaking oral presentations at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) being held in San Francisco and were featured in a CROI press conference. Merck plans to begin submitting applications for marketing authorization to regulatory agencies by mid-2025.
In the double-blind trial MK-8591A-052 (Abstract #204A), results for the primary endpoint (HIV-1 RNA ≥50 copies/mL) showed that 1.5% of participants who switched to DOR/ISL had a viral load of ≥50 copies/mL at Week 48, compared to 0.6% on BIC/FTC/TAF (treatment difference 0.9%, 95% CI -1.9, 2.9). At Week 48, 91.5% of participants who switched to DOR/ISL maintained viral suppression (HIV-1 RNA &lt;50 copies/mL) compared to 94.2% of participants who continued receiving BIC/FTC/TAF (treatment difference -2.6%, 95% CI -7.1, 2.6; secondary endpoint).
In the open-label trial MK-8591A-051 (Abstract #204B), results for the primary endpoint (HIV-1 RNA ≥50 copies/mL) showed that 1.4% of participants who received DOR/ISL had a viral load of ≥50 copies/mL at Week 48, compared to 4.9% on bART (treatment difference -3.6%, 95% CI -7.8, -0.8. At Week 48, 95.6% of participants who switched to DOR/ISL maintained viral suppression (HIV-1 RNA &lt;50 copies/mL) compared to 91.9% of participants who continued on bART (treatment difference 3.7%, 95% CI -0.3, 8.9; secondary endpoint).
Across both trials, the safety profile of DOR/ISL was generally comparable to the comparator antiretroviral regimens, including BIC/FTC/TAF in MK-8591A-052. At Week 48, the mean percent change in total lymphocyte and CD4 counts were similar for DOR/ISL and comparator regimens. No treatment-emergent resistance to DOR or ISL was observed in either trial.

Merck Announces Data From Phase 3 Trials That Show The Investigational, Once-Daily, Oral, Two-Drug Regimen Of Doravirine/Islatravir Maintained HIV-1 Viral Suppression At Week 48

Wells Fargo analyst Sam Reid maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Overweight and lowers the price target from $205 to $180.

Comments

PyroGenesis

PyroGenesis (PYRGF) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL